Clinical application of dendritic cells and interleukin-2 and tools to study activated T cells in horses-First results and implications for quality control

Veterinary Immunology and Immunopathology

Volumn 128, Issue 1-3, 2009, Pages 16-23

  Steinbach, Falko ^a   Bischoff, Sabine ^b   Freund, Hannah ^c   Metzner Flemisch, Simone ^d   Ibrahim, Sherif ^e   Walter, Jakob ^f   Wilke, Ingo ^b   Mauel, Susanne ^c  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

^b Fzmb GmbH   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d Fachtierarzt für Pferde Metzner Felmisch ^*  (Germany)

^e LEIBNIZ INSTITUTE FOR ZOO AND WILDLIFE RESEARCH   (Germany)

^f BAYER PHARMA AG   (Germany)

Author keywords

Horse; Immunology; Leukocyte differentiation; Therapy; Tumour

Indexed keywords

CD14 ANTIGEN; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HORSE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; QUALITY CONTROL; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; DENDRITIC CELLS; FORKHEAD TRANSCRIPTION FACTORS; HORSE DISEASES; HORSES; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; QUALITY CONTROL; T-LYMPHOCYTES;

CANIS FAMILIARIS; EQUIDAE; RODENTIA;

EID: 60549101048     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2008.10.317     Document Type: Article

References (32)

1. Ahmadzadeh M., and Rosenberg S.A. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107 (2006) 2409-2414
2. Belli F., Arienti F., Sule-Suso J., Clemente C., Mascheroni L., Cattelan A., Santantonio C., Gallino G.F., Melani C., Rao S., Colombo M.P., Maio M., Cascinelli N., and Parmiani G. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol. Immunother. 44 (1997) 197-203
3. Biller B.J., Elmslie R.E., Burnett R.C., Avery A.C., and Dow S.W. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet. Immunol. Immunopathol. 116 (2007) 69-78
4. Bogaert L., Martens A., De Baere C., and Gasthuys F. Detection of bovine papillomavirus DNA on the normal skin and in the habitual surroundings of horses with and without equine sarcoids. Res. Vet. Sci. 79 (2005) 253-258
5. Chambers G., Ellsmore V.A., O'Brien P.M., Reid S.W., Love S., Campo M.S., and Nasir L. Association of bovine papillomavirus with the equine sarcoid. J. Gen. Virol. 84 (2003) 1055-1062
6. Den Otter W., Hill F.W., Klein W.R., Koten J.W., Steerenberg P.A., De Mulder P.H., Rhode C., Stewart R., Faber J.A., Ruitenberg E.J., et al. Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol. Immunother. 41 (1995) 10-14
7. FDA, 2006. Guidance for Industry, Investigators, and Reviewers-Exploratory IND Studies. http://www.fda.gov/cder/guidance/index.htm.
8. Gutwald J.G., Groth W., and Mahrle G. Peritumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma. Br. J. Dermatol. 130 (1994) 541-542
9. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., and Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2 (1996) 52-58
10. Ibrahim S., Saunders K., Kydd J.H., Lunn D.P., and Steinbach F. Screening of anti-human leukocyte monoclonal antibodies for reactivity with equine leukocytes. Vet. Immunol. Immunopathol. 119 (2007) 63-80
11. Ibrahim S., and Steinbach F. Non-HLDA8 animal homologue section anti-leukocyte mAbs tested for reactivity with equine leukocytes. Vet. Immunol. Immunopathol. 119 (2007) 81-91
12. Mauel S., Steinbach F., and Ludwig H. Monocyte-derived dendritic cells from horses differ from dendritic cells of humans and mice. Immunology 117 (2006) 463-473
13. Mayordomo J.I., Zorina T., Storkus W.J., Zitvogel L., Celluzzi C., Falo L.D., Melief C.J., Ildstad S.T., Kast W.M., Deleo A.B., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1 (1995) 1297-1302
14. Mule J.J., and Rosenberg S.A. Mechanistic aspects of successful immunotherapy of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. Prog. Clin. Biol. Res. 244 (1987) 79-91
15. Peters J.H., Gieseler R., Thiele B., and Steinbach F. Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol. Today 17 (1996) 273-278
16. Paillot R., Daly J.M., Juillard V., Minke J.M., Hannant D., and Kydd J.H. Equine interferon gamma synthesis in lymphocytes after in vivo infection and in vitro stimulation with EHV-1. Vaccine 23 (2005) 4541-4551
17. Piuko K., Bravo I.G., and Muller M. Identification and characterization of equine granzyme B. Vet. Immunol. Immunopathol. 118 (2007) 239-251
18. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., and White D.E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271 (1994) 907-913
19. Saalmüller A., Lunney J.K., Daubenberger C., Davis W., Fischer U., Gobel T.W., Griebel P., Hollemweguer E., Lasco T., Meister R., Schuberth H.J., Sestak K., Sopp P., Steinbach F., Xiao-Wei W., and Aasted B. Summary of the animal homologue section of HLDA8. Cell Immunol. 236 (2005) 51-58
20. Santin A.D., Bellone S., Palmieri M., Zanolini A., Ravaggi A., Siegel E.R., Roman J.J., Pecorelli S., and Cannon M.J. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J. Virol. 82 (2008) 1968-1979
21. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2 (2002) 389-400
22. Spoormakers T.J., Klein W.R., Jacobs J.J., Van Den Ingh T.S., Koten J.W., and Den Otter W. Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2. Cancer Immunol. Immunother. 52 (2003) 179-184
23. Steinbach F., and Thiele B. Phenotypic investigation of mononuclear phagocytes by flow cytometry. J. Immunol. Methods 174 (1994) 109-122
24. Steinbach F., Krause B., and Thiele B. Monocyte derived dendritic cells (MoDC) present phenotype and functional activities of Langerhans cells/dendritic cells. Adv. Exp. Med. Biol. 378 (1995) 151-153
25. Steinbach F., Deeg C., Mauel S., and Wagner B. Equine immunology: offspring of the serum horse. Trends Immunol. 23 (2002) 223-225
26. Steinbach F., Stark R., Ibrahim S., Gawad E.A., Ludwig H., Walter J., Commandeur U., and Mauel S. Molecular cloning and characterization of markers and cytokines for equid myeloid cells. Vet. Immunol. Immunopathol. 108 (2005) 227-236
27. Stewart A.A., Rush B., and Davis E. The efficacy of intratumoural 5-fluorouracil for the treatment of equine sarcoids. Aust. Vet. J. 84 (2006) 101-106
28. Tamura K., Yamada M., Isotani M., Arai H., Yagihara H., Ono K., Washizu T., and Bonkobara M. Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells. Vet. J. (2007)
29. Timmerman J.M., and Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50 (1999) 507-529
30. Walker M.R., Carson B.D., Nepom G.T., Ziegler S.F., and Buckner J.H. De novo generation of antigen-specific CD4+ CD25+ regulatory T cells from human CD4+ CD25-cells. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 4103-4108
31. Xu J., Cai J., Anderson B., Wagner B., Albrecht R., Peek S.F., Suresh M., and Darien B.J. Cloning and functional characterization of recombinant equine P-selectin. Vet. Immunol. Immunopathol. 116 (2007) 115-130
32. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6 (2006) 295-307